EE+ POEM Archive
Efpeglenatide reduces the risk of major adverse CV events in patients with T2DM + established CVD or chronic kidney disease (AMPLITUDE-O)
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Efpeglenatide Reduces the Risk of Major Adverse CV Events in Patients With T2DM + Established CVD or Chronic Kidney Disease (AMPLITUDE-O)." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315498/all/Efpeglenatide_reduces_the_risk_of_major_adverse_CV_events_in_patients_with_T2DM_+_established_CVD_or_chronic_kidney_disease__AMPLITUDE_O_.
Efpeglenatide reduces the risk of major adverse CV events in patients with T2DM + established CVD or chronic kidney disease (AMPLITUDE-O). In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315498/all/Efpeglenatide_reduces_the_risk_of_major_adverse_CV_events_in_patients_with_T2DM_+_established_CVD_or_chronic_kidney_disease__AMPLITUDE_O_. Accessed April 17, 2024.
Efpeglenatide reduces the risk of major adverse CV events in patients with T2DM + established CVD or chronic kidney disease (AMPLITUDE-O). (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315498/all/Efpeglenatide_reduces_the_risk_of_major_adverse_CV_events_in_patients_with_T2DM_+_established_CVD_or_chronic_kidney_disease__AMPLITUDE_O_
Efpeglenatide Reduces the Risk of Major Adverse CV Events in Patients With T2DM + Established CVD or Chronic Kidney Disease (AMPLITUDE-O) [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 April 17]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315498/all/Efpeglenatide_reduces_the_risk_of_major_adverse_CV_events_in_patients_with_T2DM_+_established_CVD_or_chronic_kidney_disease__AMPLITUDE_O_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Efpeglenatide reduces the risk of major adverse CV events in patients with T2DM + established CVD or chronic kidney disease (AMPLITUDE-O)
ID - 1315498
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315498/all/Efpeglenatide_reduces_the_risk_of_major_adverse_CV_events_in_patients_with_T2DM_+_established_CVD_or_chronic_kidney_disease__AMPLITUDE_O_
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
